Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaenomeles sinensis extract is derived from the fruit of the Chinese quince, a plant species native to East Asia and traditionally utilized in Korean and Chinese medicine. Research suggests that the extract, particularly its constituent stearic acid methyl ester (SAME), functions as an activator of choline acetyltransferase (ChAT), the enzyme responsible for the biosynthesis of acetylcholine. By enhancing ChAT activity, the extract aims to restore cholinergic function, which is often compromised in neurodegenerative conditions. Preclinical studies in mice have demonstrated that Chaenomeles sinensis extract can significantly improve learning and memory deficits induced by neurotoxins like trimethyltin (TMT), positioning it as a potential therapeutic candidate for the treatment of Alzheimer's disease and other cognitive disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chaenomeles sinensis extract.